Global X Autonomous & Electric Vehicles vs Eli Lilly And Co — how do they compare? Global X Autonomous & Electric Vehicles trades at $32.44 (market cap $356.37M), while Eli Lilly And Co trades at $1,166.44 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 2918.3× Global X Autonomous & Electric Vehicles's market cap, and Eli Lilly And Co pays a 0.59% dividend while Global X Autonomous & Electric Vehicles pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Autonomous & Electric Vehicles for 40 Days and Eli Lilly And Co for 93 Days on average.
| DRIV | LLY | |
|---|---|---|
Market Cap | $356.37M | $1.04T |
Volume | 22,397 | 3,064,878 |
Sector | Sector/Thematic | Health |
52-Week High | $42.53 | $1.28K |
52-Week Low | $27.58 | $799.57 |
Typical Hold Time | 40 Days | 93 Days |
Enterprise Value | — | $1.09T |
Dividend Yield | — | 0.59% |
Signals from Pluang's Aura AI — not financial advice
DRIV trades at $33.37, down 1.68% today amid mixed technical signals. The overall technical outlook is bullish with neutral oscillators, while key support sits at $33. Recent news highlights automotive sector focus on hybrid and electric vehicles, though company-specific financial ratios are currently unavailable for analysis.
The stock shows technical resilience near support levels with bullish momentum indicators. Investment appeal hinges on forthcoming financial disclosures and sector trends favoring EV/hybrid adoption. Key risks include sector competition and reliance on broader automotive market performance without current fundamental data.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% on the day, with a bullish technical signal and strong fundamentals. Recent earnings beats, robust revenue growth to $65.18B in 2025, and a net income margin of 33.53% highlight operational strength. Positive news flow centers on next-generation weight-loss drugs, with analyst consensus bullish and a price target of $1,350.
Outlook remains positive given pipeline catalysts in obesity/diabetes markets, though high valuations (P/E 39.9) and rising debt levels pose risks. Competitive intensity and regulatory scrutiny are watchpoints, but institutional support and earnings momentum underpin further upside potential.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →